Stallion India Fluorochemicals Unveils Investor Presentation Highlighting Robust Growth and Strategic Expansion
Stallion India Fluorochemicals released an investor presentation outlining significant expansion plans. Key developments include the upcoming R-32 manufacturing facility at Bhilwara, with a ₹250 crore topline potential in FY26-27, and the commencement of operations at the Khalapur helium processing facility. The company projects a 30-35% CAGR for the next three years.
The expansion into new facilities, strategic partnerships, and strong financial projections are expected to have a substantial positive impact on the company's future performance and market position.
The announcement details significant strategic expansions, new facility commencements, and positive financial projections, indicating a strong growth outlook for the company.
Stallion India Fluorochemicals Limited has released an investor presentation detailing its financial results for the quarter ended June 30, 2026, and outlining its strategic growth initiatives. The company is strengthening its pan-India manufacturing and distribution network with five operational facilities and an upcoming R-32 manufacturing facility at Bhilwara.
The Khalapur facility is set to commence commercial operations for high-purity helium processing with a capacity of 1,200 metric tonnes per annum. Additionally, the Mambattu facility is progressing as planned and is expected to begin operations by the end of 2026, enhancing distribution reach in South India.
The company is also advancing its backward integration strategy with a 10,000 MT R-32 manufacturing facility at Bhilwara, which aims to improve cost efficiencies and supply chain reliability. This facility received Environmental Clearance (EC) on December 28, 2025, from SEIAA, Rajasthan. Construction has commenced, targeting completion in approximately 8 months, with expected commissioning in October 2026. This project is projected to generate ₹250 crore in topline in FY26-27 and ₹500-600 crore in FY27-28, with an expected PAT margin of 22–24%.
Stallion India Fluorochemicals has also entered into a long-term strategic sourcing partnership with Sharjah Oxygen Company L.L.C. for liquid helium. The company anticipates improving EBITDA margins by approximately 3-4% over the medium term through its expansion into next-generation HFOs and specialty gases.
Financially, the company reported a total revenue of ₹11,054.56 lakh for Q1 FY26-27, a 12.78% increase year-on-year, with EBITDA growing by 75.85% to ₹2,526.79 lakh and PAT rising by 79.15% to ₹1,856.55 lakh. The company projects a 30-35% CAGR for the next three years with sustainable margins.
What to do with a filing like this
Stallion India Fluorochemicals Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Stallion India Fluorochemicals Limited. Read the original for the full detail.